Evidence map›Paper›PMID 32451587›Full record

ArticleApplied microbiology and biotechnology2020

Unraveling the anti-biofilm potential of green algal sulfated polysaccharides against Salmonella enterica and Vibrio harveyi.

Jyoti Vishwakarma, Sirisha V L

Abstract read
PubMed Publisher
In one paragraph

Article in Applied microbiology and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Molecular Aspects of the Functioning of Pathogenic Bacteria Biofilm Based onInternational journal of molecular sciences · 2024
    Review
  7. Article
  8. Combating planktonic and biofilm growth of Serratia marcescens by repurposing ebselen.International microbiology : the official journal of the Spanish Society for Microbiology · 2023
    Article
  9. Review
  10. Tryptone-stabilized silver nanoparticles' potential to mitigate planktonic and biofilm growth forms of Serratia marcescens.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2023
    Article
  11. Inhibition ofFoods (Basel, Switzerland) · 2022
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Influence of Polysaccharides FromFrontiers in microbiology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jyoti VishwakarmaSchool of Biological Sciences, UM-DAE Centre for Excellence in Basic Sciences, University of Mumbai, Kalina Campus, Vidyanagari, Mumbai, 400098, India.
Sirisha V LSchool of Biological Sciences, UM-DAE Centre for Excellence in Basic Sciences, University of Mumbai, Kalina Campus, Vidyanagari, Mumbai, 400098, India. sirisha@cbs.ac.in.ORCID http://orcid.org/0000-0001-5001-0272
University of Mumbai · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the main reasons for the bacterial resistance to antibiotics is caused by biofilm formation of microbial pathogens during bacterial infections. Salmonella enterica and Vibrio harveyi are known to form biofilms and represent a major health concern worldwide, causing human infections responsible for morbidity and mortality. The current study aims to investigate the effect of purified sulfated polysaccharides (SPs) from Chlamydomonas reinhardtii (Cr) on planktonic and biofilm growth of these bacteria. The effect of Cr-SPs on bacterial planktonic growth was assessed by using the agar well diffusion method, which showed clear zones ranging from 13 to 26 mm in diameter from 0.5 to 8 mg/mL of Cr-SPs against both the bacteria. Time-kill activity and reduction in clonogenic propagation further help to understand the anti-microbial potential of Cr-SPs. The minimum inhibitory concentration of Cr-SPs against S. enterica and V. harveyi was as low as 440 μg/mL and 490 μg/mL respectively. Cr-SPs inhibited bacterial cell attachment up to 34.65-100% at 0.5-8 mg/mL in S. enterica and V. harveyi respectively. Cr-SPs also showed 2-fold decrease in the cell surface hydrophobicity, indicating their potential to prevent bacterial adherence. Interestingly, Cr-SPs efficiently eradicated the preformed biofilms. Increased reduction in total extracellular polysaccharide (EPS) and extracellular DNA (eDNA) content in a dose-dependent manner demonstrates Cr-SPs ability to interact and destroy the bacterial EPS layer. SEM analysis showed that Cr-SPs effectively distorted preformed biofilms and also induced morphological changes. Furthermore, Cr-SPs also showed anti-quorum-sensing potential by reducing bacterial urease and protease activities. These results indicate the potential of Cr-SPs as an anti-biofilm agent and will help to develop them as alternative therapeutics against biofilm-forming bacterial infections. KEY POINTS: • Cr-SPs not only inhibited biofilm formation but also eradicated preformed biofilms. • Cr-SPs altered bacterial cell surface hydrophobicity preventing biofilm formation. • Cr-SPs efficiently degraded eDNA of the EPS layer disrupting mature biofilms. • Cr-SPs reduced activity of quorum-sensing-mediated enzymes like protease and urease.

Indexed as

Anti-Bacterial AgentsBacterial AdhesionBiofilmsChlamydomonas reinhardtiiChlorophytaDNA, BacterialMicrobial Sensitivity TestsPlant ExtractsPolysaccharidesPolysaccharides, BacterialQuorum SensingSalmonella entericaSulfatesVibrioAnti-Bacterial AgentsDNA, BacterialPlant ExtractsPolysaccharidesPolysaccharides, BacterialSulfatesAlgal sulfated polysaccharidesAntibacterial activityAnti-biofilm activityAnti-quorum-sensing activityBacterial infections

Identifiers

PMID32451587
OpenAlexW3031064692

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.